Prognostic importance of the inflammation-based Glasgow prognostic score in patients with gastric cancer
Menée sur 1 710 patients atteints d'un cancer gastrique et traités par chirurgie entre 2000 et 2007, cette étude évalue l'association entre le système de score mGPS (Glasgow Pronostic Score), basé sur la concentration plasmatique pré-opératoire en protéine C réactive et en albumine, et la survie des patients
Background : The inflammation-based Glasgow prognostic score (GPS) has been shown to be a prognostic factor for a variety of tumours. This study investigates the significance of the modified GPS (mGPS) for the prognosis of patients with gastric cancer.
Methods : The mGPS (0=C-reactive protein (CRP)less than or equal to10 mg l−1, 1=CRP>10 mg l−1 and 2=CRP>10 mg l−1 and albumin<35 g l−1) was calculated on the basis of preoperative data for 1710 patients with gastric cancer who underwent surgery between January 2000 and December 2007. Patients were given an mGPS of 0, 1 or 2. The prognostic significance was analysed by univariate and multivariate analyses.
Results : Increased mGPS was associated with male patient, old age, low body mass index, increased white cell count and neutrophils, elevated carcinoembryonic antigen and CA19-9 and advanced tumour stage. Kaplan–Meier analysis and log-rank test revealed that a higher mGPS predicted a higher risk of postoperative mortality in both relative early-stage (stage I; P<0.001) and advanced-stage cancer (stage II, III and IV; P<0.001). Multivariate analysis demonstrated the mGPS to be a risk factor for postoperative mortality (odds ratio 1.845; 95% confidence interval 1.184–2.875; P=0.007).
Conclusion : The preoperative mGPS is a simple and useful prognostic factor for postoperative survival in patients with gastric cancer.
British Journal of Cancer , résumé, 2011